Guardion® Appoints Experienced Executive to Lead Development and Expansion of Recently-Acquired NutriGuard Business Line
January 07 2020 - 11:02AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI), a leader in the field of ocular health technologies
and products, announced that it has hired John P. Troup, PhD to
serve as President of the Company’s NutriGuard business line, which
was acquired by the Company effective as of September 20, 2019. The
NutriGuard business, with a 30-year operating history, is expected
to provide the Company with a direct-to-consumer (“DTC”)
capability. The Company’s objective is to develop NutriGuard into a
globally-recognized and respected, physician-preferred
nutraceuticals brand.
Dr. Troup is a dynamic, innovative and
experienced executive with an extensive management background
working at market-leading healthcare companies in the health, food
and nutritional supplement segments. With a proven 25-year track
record of directing commercially successful growth initiatives, Dr.
Troup has been able to establish effective product and brand
differentiation in various highly-competitive Consumer Packaged
Goods (“CPG”) categories.
Michael Favish, Guardion’s Chief Executive
Officer, commenting on the appointment of Dr. Troup, said
“NutriGuard represents a key component of Guardion’s plans to
develop and expand its nutraceutical portfolio in 2020, and we are
delighted to have an executive of Dr. Troup’s caliber and
reputation joining our team to lead this endeavor.”
About Guardion Health Sciences,
Inc.
Guardion® is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with an
initial medical food product that addresses a depleted macular
protective pigment, a known risk factor for age-related macular
degeneration (“AMD”), and a significant component of functional
vision performance. Guardion® has also developed a proprietary
medical device, the MapcatSF®, which accurately measures the
macular pigment density, therefore providing the only two-pronged
evidence-based protocol for the treatment of a depleted macular
protective pigment.
About VectorVision®
VectorVision® specializes in the standardization
of contrast sensitivity, glare sensitivity, low contrast acuity,
and ETDRS acuity vision testing. Its patented standardization
system provides the practitioner or researcher the ability to
delineate very small changes in visual capability, either as
compared to the population or from visit to visit. VectorVision®’s
CSV-1000 device is considered the standard of care for clinical
trials. VectorVision® is a wholly-owned subsidiary of Guardion.
Guardion has completed development of the
proprietary VectorVision® CSV-2000 standardized contrast
sensitivity test and recently introduced the commercial product to
the marketplace. The CSV-2000 is the only computer-generated vision
testing instrument available that will provide the optical
marketplace with the Company’s proprietary, industry-standard
contrast sensitivity test, along with a full suite of standard
vision testing protocols. The proprietary standardization
methodology incorporated into the CSV-2000 includes a patented
technology known as AcQvizTM that automatically and constantly
measures and adjusts screen luminance to a fixed standard light
level for vision testing.
About NutriGuard
NutriGuard formulates high-quality,
scientifically-credible nutraceuticals, which are designed to
supplement consumers’ diets and assist in treating/preventing
diseases. NutriGuard uses pharmaceutical standards to establish the
safety and efficacy of the products it develops and markets, and
also maintains that commitment through rigorous manufacturing and
quality assurance programs. Guardion’s plan is to increase
NutriGuard’s existing customer base and build on its product
platform by making NutriGuard products available to patients
directly and through recommendations by their physicians.
Forward-Looking Statement
Disclaimer
Certain statements in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient capital
on a timely basis in order to implement its business plan and its
ability to successfully develop and commercialize its proprietary
products and technologies. Readers are cautioned not to place undue
reliance on these forward-looking statements, as actual results
could differ materially from those described in the forward-looking
statements contained herein. Readers are urged to read the risk
factors set forth under the caption “Risk Factors” in the
Company’s’ Annual Report on Form 10-K for the year ended December
31, 2018 and the Company’s other filings made with SEC, which are
available at the SEC’s website (www.sec.gov). Forward-looking
statements included herein are made as of the date hereof, and the
Company does not undertake any obligation to update publicly such
statements to reflect subsequent events or circumstances.
Investor Relations Contact: Matthew
AbenantePorter, LeVay & Rose Telephone: (212) 564-4700 E-mail:
matthew@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Apr 2023 to Apr 2024